<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01553747</url>
  </required_header>
  <id_info>
    <org_study_id>27018966IBS3002</org_study_id>
    <secondary_id>2012-001601-24</secondary_id>
    <nct_id>NCT01553747</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Furiex Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Furiex Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy, safety, and tolerability of different
      doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants
      with diarrhea-predominant irritable bowel syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2012</start_date>
  <completion_date type="Actual">January 9, 2014</completion_date>
  <primary_completion_date type="Actual">January 9, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Composite responders were defined as participants who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Composite responders were defined as participants who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Pain Responders In Daily Worst Abdominal Pain Scores by Intervals</measure>
    <time_frame>12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)</time_frame>
    <description>Pain responders were defined as participants who met the daily pain response criteria (ie, the worst abdominal pain score in the past 24 hours improved by ≥30% compared to baseline) for at least 50% of days with diary entries during each interval. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Responders In Daily Stool Consistency Scores by Intervals</measure>
    <time_frame>12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)</time_frame>
    <description>Stool consistency responders: Participants who met daily stool consistency response criterion (ie,score of 1, 2, 3, or 4 or absence of bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain) for at least 50% of days with diary entries during each interval. BSS was defined as 7-point Scale in which score of 1= separate hard lumps, 2= sausage shaped but lumpy, 3= sausage-like with cracks on the surface, 4= sausage-like but smooth and soft, 5= soft blobs with clear cut edges, 6= fluffy pieces with ragged edges, and 7= watery with no solid pieces. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over 12-week interval, and a minimum of 110 days of diary entries over 26-week interval to be a responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Responders In Irritable Bowel Syndrome, Diarrhea Predominant (IBS-d) Global Symptom Scale by Intervals</measure>
    <time_frame>12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)</time_frame>
    <description>IBS-d global symptom responders were defined as those participants who met the daily IBS-d global symptom response criteria (ie, IBS-d global symptom score of 0 [none] or 1 [mild]; or a daily IBS-d global symptom score improved by ≥2.0 compared to the baseline average) for at least 50% of days with diary entries during each interval. IBS-d Global Symptom Scale was a 5-point scale, score ranging from 0 to 4. 0= no symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms and 4 = very severe symptoms. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Responders to the Irritable Bowel Syndrome Quality of Life Measure (IBS-QoL) Scale</measure>
    <time_frame>Weeks 4, 8, 12, 18, 26 and 30 (End of Treatment [EOT])</time_frame>
    <description>IBS-QoL responders were defined as participants who achieved at least a 14-point improvement in IBS-QoL total score from baseline to the applicable visit. The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100-point (0= worst; 100=better) scale for ease of interpretation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Irritable Bowel Syndrome - Adequate Relief (IBS-AR) Scale</measure>
    <time_frame>12-week interval (Weeks 1-12) and 26-week interval (Weeks 1-26)</time_frame>
    <description>Adequate relief of IBS symptoms was assessed once weekly by participants answering the IBS-AR item in the electronic diary. IBS-AR responders were defined as participants with a weekly response of &quot;Yes&quot; to adequate relief of their IBS symptoms for at least 50% of the total weeks during the interval. A participant must have had a positive response on ≥6 weeks for the 12-week interval and ≥13 weeks for the 26-week interval, regardless of diary compliance, to be a responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Abdominal Discomfort Scores</measure>
    <time_frame>Baseline, Weeks 4, 12 and 26</time_frame>
    <description>Symptoms of abdominal discomfort were recorded on a 0 to 10 scale, where 0 corresponded to no discomfort and 10 corresponded to worst imaginable discomfort. A negative change from Baseline indicates the discomfort decreased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Abdominal Bloating Scores</measure>
    <time_frame>Baseline, Weeks 4, 12 and 26</time_frame>
    <description>Symptoms of abdominal bloating were recorded on a 0 to 10 scale, where 0 corresponded to no bloating and 10 corresponded to worst imaginable bloating. A negative change from Baseline indicates the bloating decreased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bowel Movements Per Day</measure>
    <time_frame>Weeks 4, 12 and 26</time_frame>
    <description>Participants recorded the number of bowel movements over 24 hours daily throughout the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bowel Incontinence Episodes</measure>
    <time_frame>Weeks 4, 12 and 26</time_frame>
    <description>Participants recorded the number of incontinence episodes over 24 hours daily throughout the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bowel Incontinence Free Days</measure>
    <time_frame>Weeks 4, 12 and 26</time_frame>
    <description>An incontinence free day was one where the participant reports zero incontinence episodes. The number of incontinence free days for a participant was assessed each week based on the number of reported days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Urgency Episodes Per Day</measure>
    <time_frame>Weeks 4, 12 and 26</time_frame>
    <description>Participants recorded the number of urgency episodes over 24 hours daily throughout the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IBS-QoL Total Scores</measure>
    <time_frame>Baseline, Weeks 4, 8, 12, 18, 26 and 30/EOT</time_frame>
    <description>The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100- point scale (0=worst; 100=better) for ease of interpretation. A positive change from Baseline indicates that quality of life improved.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1146</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Eluxadoline 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eluxadoline 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eluxadoline</intervention_name>
    <description>Oral tablets twice daily</description>
    <arm_group_label>Eluxadoline 100 mg</arm_group_label>
    <arm_group_label>Eluxadoline 75 mg</arm_group_label>
    <other_name>JNJ-27018966</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant is 18 to 80 years old

          2. Participant has a diagnosis of irritable bowel syndrome (IBS) with a subtype of
             diarrhea defined by the Rome III criteria.

        2. Participant has had a colonoscopy performed:

          -  Within 10 years prior to Prescreening if participant is at least 50 years of age
             (sigmoidoscopy, double contrast barium enema, or computed tomography (CT) colonography
             within the past 5 years is acceptable)

          -  Since the onset (if applicable) of any of the following alarm features for
             participants of any age

               -  Participant has documented weight loss within the past 6 months

               -  Participant has nocturnal symptoms

               -  Participant has a familial history of first-degree relatives with colon cancer

               -  Participant has blood mixed with their stool (excluding blood from hemorrhoids).

                  3. Female participants must be:

          -  Postmenopausal, defined as 52 years or older and amenorrheic for at least 2 years at
             Prescreening,

          -  Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation,
             or otherwise be incapable of pregnancy),

          -  Abstinent, or

          -  If sexually active, be practicing an effective method of birth control.

        Exclusion Criteria:

          1. Participant has a diagnosis of IBS with a subtype of constipation, mixed IBS, or
             unsubtyped IBS by the Rome III criteria.

          2. Participant has a history of inflammatory or immune-mediated gastrointestinal (GI)
             disorders including inflammatory bowel disease (ie, Crohn's disease, ulcerative
             colitis) and celiac disease.

          3. Participant has a history of diverticulitis within 3 months prior to Prescreening.

          4. Participant has a history of intestinal obstruction, stricture, toxic megacolon, GI
             perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic
             colitis, or impaired intestinal circulation (eg, aortoiliac disease).

          5. Participant has any of the following surgical history:

               -  Cholecystectomy with any history of post cholecystectomy biliary tract pain

               -  Any abdominal surgery within the 3 months prior to Prescreening

               -  Participant has a history of major gastric, hepatic, pancreatic, or intestinal
                  surgery (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months
                  post surgery are allowed)

        Other protocol-specific eligibility criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Alabama</state>
        <zip>35603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Sherwood</city>
        <state>Arkansas</state>
        <zip>72120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>La Mirada</city>
        <state>California</state>
        <zip>90638</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Eustis</city>
        <state>Florida</state>
        <zip>32726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Plant City</city>
        <state>Florida</state>
        <zip>33563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <zip>30092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <zip>60101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hammond</city>
        <state>Illinois</state>
        <zip>46324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <zip>46112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Granger</city>
        <state>Indiana</state>
        <zip>46530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <zip>50325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <zip>67124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hollywood</city>
        <state>Maryland</state>
        <zip>20636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Cadillac</city>
        <state>Michigan</state>
        <zip>49601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hazelwood</city>
        <state>Missouri</state>
        <zip>63042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Elkhorn</city>
        <state>Nebraska</state>
        <zip>68022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Blackwood</city>
        <state>New Jersey</state>
        <zip>08012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11367</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hollis</city>
        <state>New York</state>
        <zip>11423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Dunn</city>
        <state>North Carolina</state>
        <zip>28334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Beavercreek</city>
        <state>Ohio</state>
        <zip>45431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Groveport</city>
        <state>Ohio</state>
        <zip>43125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <zip>45806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Tiffin</city>
        <state>Ohio</state>
        <zip>44883</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Scottdale</city>
        <state>Pennsylvania</state>
        <zip>15683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02888</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>North Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Athens</city>
        <state>Tennessee</state>
        <zip>37303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Columbia</city>
        <state>Tennessee</state>
        <zip>38401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>West Valley City</city>
        <state>Utah</state>
        <zip>84120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Christiansburg</city>
        <state>Virginia</state>
        <zip>24073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Monroe</city>
        <state>Wisconsin</state>
        <zip>53566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 3G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1E 2E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7M 4Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hawkesbury</city>
        <state>Ontario</state>
        <zip>K6A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Vaughan</city>
        <state>Ontario</state>
        <zip>L4L 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>San Juan</city>
        <zip>00926-2832</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chestfield</city>
        <state>Kent</state>
        <zip>CT5 3QS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Blackpool</city>
        <state>Lancashire</state>
        <zip>FY4 3AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>County Durham</city>
        <zip>DL14 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Durham</city>
        <zip>DH1 5TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Wigan</city>
        <zip>WN1 2NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2012</study_first_posted>
  <results_first_submitted>June 11, 2018</results_first_submitted>
  <results_first_submitted_qc>July 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2018</results_first_posted>
  <disposition_first_submitted>March 25, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 25, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 21, 2014</disposition_first_posted>
  <last_update_submitted>July 27, 2018</last_update_submitted>
  <last_update_submitted_qc>July 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable bowel syndrome with diarrhea</keyword>
  <keyword>Irritable bowel syndrome</keyword>
  <keyword>Diarrhea predominant irritable bowel syndrome</keyword>
  <keyword>Colonic diseases</keyword>
  <keyword>Colonic diseases, functional</keyword>
  <keyword>Digestive system disease</keyword>
  <keyword>Gastrointestinal disease</keyword>
  <keyword>Intestinal disease</keyword>
  <keyword>Colonic pseudo-obstruction</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Signs and symptoms, Digestive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eluxadoline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>3356 participants were prescreened and entered into interactive voice response system for participation in the study. 1146 participants were randomized. One participant was unintentionally randomized twice and was assigned 2 different participant identification numbers due to participant trying to participate at more than 1 study center at once.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Eluxadoline 75 mg</title>
          <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
        </group>
        <group group_id="P2">
          <title>Eluxadoline 100 mg</title>
          <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="381"/>
                <participants group_id="P2" count="383"/>
                <participants group_id="P3" count="382"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Attended Week 12 Visit</title>
              <participants_list>
                <participants group_id="P1" count="296"/>
                <participants group_id="P2" count="301"/>
                <participants group_id="P3" count="312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Attended Week 26 Visit</title>
              <participants_list>
                <participants group_id="P1" count="259"/>
                <participants group_id="P2" count="271"/>
                <participants group_id="P3" count="278"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participated in Blinded-Placebo Period</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="253"/>
                <participants group_id="P3" count="272"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="264"/>
                <participants group_id="P3" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="119"/>
                <participants group_id="P3" count="109"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntarily withdrew</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="74"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event or SAE</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician decision: other</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision, specify</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician decision: lack of efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled set included all participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Eluxadoline 75 mg</title>
          <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
        </group>
        <group group_id="B2">
          <title>Eluxadoline 100 mg</title>
          <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="381"/>
            <count group_id="B2" value="383"/>
            <count group_id="B3" value="382"/>
            <count group_id="B4" value="1146"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="13.17"/>
                    <measurement group_id="B2" value="45.7" spread="13.31"/>
                    <measurement group_id="B3" value="47.1" spread="13.82"/>
                    <measurement group_id="B4" value="45.9" spread="13.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="198"/>
                    <measurement group_id="B4" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="250"/>
                    <measurement group_id="B4" value="768"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores</title>
        <description>Composite responders were defined as participants who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Intention-to-treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores</title>
          <description>Composite responders were defined as participants who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.</description>
          <population>Intention-to-treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="29.6"/>
                    <measurement group_id="O3" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The family-wise error rate was controlled by Bonferroni adjustment for each active dose versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Significance level of 0.025</p_value_desc>
            <method>Chi-square test statistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The family-wise error rate was controlled by Bonferroni adjustment for each active dose versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Significance level of 0.025</p_value_desc>
            <method>Chi-square test statistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores</title>
        <description>Composite responders were defined as participants who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.</description>
        <time_frame>Up to 26 weeks</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores</title>
          <description>Composite responders were defined as participants who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="32.7"/>
                    <measurement group_id="O3" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The family-wise error rate was controlled by Bonferroni adjustment for each active dose versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Significance level of 0.025</p_value_desc>
            <method>Chi-square test statistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The family-wise error rate was controlled by Bonferroni adjustment for each active dose versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Significance level of 0.025</p_value_desc>
            <method>Chi-square test statistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Pain Responders In Daily Worst Abdominal Pain Scores by Intervals</title>
        <description>Pain responders were defined as participants who met the daily pain response criteria (ie, the worst abdominal pain score in the past 24 hours improved by ≥30% compared to baseline) for at least 50% of days with diary entries during each interval. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.</description>
        <time_frame>12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Pain Responders In Daily Worst Abdominal Pain Scores by Intervals</title>
          <description>Pain responders were defined as participants who met the daily pain response criteria (ie, the worst abdominal pain score in the past 24 hours improved by ≥30% compared to baseline) for at least 50% of days with diary entries during each interval. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders during Weeks 1-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="51.0"/>
                    <measurement group_id="O3" value="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7"/>
                    <measurement group_id="O2" value="46.6"/>
                    <measurement group_id="O3" value="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 5-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0"/>
                    <measurement group_id="O2" value="52.9"/>
                    <measurement group_id="O3" value="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 9-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="50.3"/>
                    <measurement group_id="O3" value="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 13-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2"/>
                    <measurement group_id="O2" value="49.0"/>
                    <measurement group_id="O3" value="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 17-20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="47.4"/>
                    <measurement group_id="O3" value="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 21-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="46.9"/>
                    <measurement group_id="O3" value="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Responders In Daily Stool Consistency Scores by Intervals</title>
        <description>Stool consistency responders: Participants who met daily stool consistency response criterion (ie,score of 1, 2, 3, or 4 or absence of bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain) for at least 50% of days with diary entries during each interval. BSS was defined as 7-point Scale in which score of 1= separate hard lumps, 2= sausage shaped but lumpy, 3= sausage-like with cracks on the surface, 4= sausage-like but smooth and soft, 5= soft blobs with clear cut edges, 6= fluffy pieces with ragged edges, and 7= watery with no solid pieces. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over 12-week interval, and a minimum of 110 days of diary entries over 26-week interval to be a responder.</description>
        <time_frame>12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Responders In Daily Stool Consistency Scores by Intervals</title>
          <description>Stool consistency responders: Participants who met daily stool consistency response criterion (ie,score of 1, 2, 3, or 4 or absence of bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain) for at least 50% of days with diary entries during each interval. BSS was defined as 7-point Scale in which score of 1= separate hard lumps, 2= sausage shaped but lumpy, 3= sausage-like with cracks on the surface, 4= sausage-like but smooth and soft, 5= soft blobs with clear cut edges, 6= fluffy pieces with ragged edges, and 7= watery with no solid pieces. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over 12-week interval, and a minimum of 110 days of diary entries over 26-week interval to be a responder.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders during Weeks 1-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0"/>
                    <measurement group_id="O2" value="35.6"/>
                    <measurement group_id="O3" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="39.8"/>
                    <measurement group_id="O3" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                    <measurement group_id="O2" value="37.2"/>
                    <measurement group_id="O3" value="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 5-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="38.2"/>
                    <measurement group_id="O3" value="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 9-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="39.3"/>
                    <measurement group_id="O3" value="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 13-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="41.4"/>
                    <measurement group_id="O3" value="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 17-20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9"/>
                    <measurement group_id="O2" value="36.1"/>
                    <measurement group_id="O3" value="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 21-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="38.2"/>
                    <measurement group_id="O3" value="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Responders In Irritable Bowel Syndrome, Diarrhea Predominant (IBS-d) Global Symptom Scale by Intervals</title>
        <description>IBS-d global symptom responders were defined as those participants who met the daily IBS-d global symptom response criteria (ie, IBS-d global symptom score of 0 [none] or 1 [mild]; or a daily IBS-d global symptom score improved by ≥2.0 compared to the baseline average) for at least 50% of days with diary entries during each interval. IBS-d Global Symptom Scale was a 5-point scale, score ranging from 0 to 4. 0= no symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms and 4 = very severe symptoms. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.</description>
        <time_frame>12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Responders In Irritable Bowel Syndrome, Diarrhea Predominant (IBS-d) Global Symptom Scale by Intervals</title>
          <description>IBS-d global symptom responders were defined as those participants who met the daily IBS-d global symptom response criteria (ie, IBS-d global symptom score of 0 [none] or 1 [mild]; or a daily IBS-d global symptom score improved by ≥2.0 compared to the baseline average) for at least 50% of days with diary entries during each interval. IBS-d Global Symptom Scale was a 5-point scale, score ranging from 0 to 4. 0= no symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms and 4 = very severe symptoms. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders during Weeks 1-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6"/>
                    <measurement group_id="O2" value="42.4"/>
                    <measurement group_id="O3" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="43.2"/>
                    <measurement group_id="O3" value="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2"/>
                    <measurement group_id="O2" value="36.9"/>
                    <measurement group_id="O3" value="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 5-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="45.0"/>
                    <measurement group_id="O3" value="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 9-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9"/>
                    <measurement group_id="O2" value="43.5"/>
                    <measurement group_id="O3" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 13-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 17-20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5"/>
                    <measurement group_id="O2" value="40.8"/>
                    <measurement group_id="O3" value="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 21-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="41.6"/>
                    <measurement group_id="O3" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Responders to the Irritable Bowel Syndrome Quality of Life Measure (IBS-QoL) Scale</title>
        <description>IBS-QoL responders were defined as participants who achieved at least a 14-point improvement in IBS-QoL total score from baseline to the applicable visit. The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100-point (0= worst; 100=better) scale for ease of interpretation.</description>
        <time_frame>Weeks 4, 8, 12, 18, 26 and 30 (End of Treatment [EOT])</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Responders to the Irritable Bowel Syndrome Quality of Life Measure (IBS-QoL) Scale</title>
          <description>IBS-QoL responders were defined as participants who achieved at least a 14-point improvement in IBS-QoL total score from baseline to the applicable visit. The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100-point (0= worst; 100=better) scale for ease of interpretation.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="45.5"/>
                    <measurement group_id="O3" value="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3"/>
                    <measurement group_id="O2" value="49.5"/>
                    <measurement group_id="O3" value="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="45.0"/>
                    <measurement group_id="O3" value="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4"/>
                    <measurement group_id="O2" value="44.8"/>
                    <measurement group_id="O3" value="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 30 /EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3"/>
                    <measurement group_id="O2" value="53.9"/>
                    <measurement group_id="O3" value="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Irritable Bowel Syndrome - Adequate Relief (IBS-AR) Scale</title>
        <description>Adequate relief of IBS symptoms was assessed once weekly by participants answering the IBS-AR item in the electronic diary. IBS-AR responders were defined as participants with a weekly response of &quot;Yes&quot; to adequate relief of their IBS symptoms for at least 50% of the total weeks during the interval. A participant must have had a positive response on ≥6 weeks for the 12-week interval and ≥13 weeks for the 26-week interval, regardless of diary compliance, to be a responder.</description>
        <time_frame>12-week interval (Weeks 1-12) and 26-week interval (Weeks 1-26)</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Irritable Bowel Syndrome - Adequate Relief (IBS-AR) Scale</title>
          <description>Adequate relief of IBS symptoms was assessed once weekly by participants answering the IBS-AR item in the electronic diary. IBS-AR responders were defined as participants with a weekly response of &quot;Yes&quot; to adequate relief of their IBS symptoms for at least 50% of the total weeks during the interval. A participant must have had a positive response on ≥6 weeks for the 12-week interval and ≥13 weeks for the 26-week interval, regardless of diary compliance, to be a responder.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders during Weeks 1-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1"/>
                    <measurement group_id="O2" value="58.4"/>
                    <measurement group_id="O3" value="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8"/>
                    <measurement group_id="O2" value="53.7"/>
                    <measurement group_id="O3" value="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Abdominal Discomfort Scores</title>
        <description>Symptoms of abdominal discomfort were recorded on a 0 to 10 scale, where 0 corresponded to no discomfort and 10 corresponded to worst imaginable discomfort. A negative change from Baseline indicates the discomfort decreased.</description>
        <time_frame>Baseline, Weeks 4, 12 and 26</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Abdominal Discomfort Scores</title>
          <description>Symptoms of abdominal discomfort were recorded on a 0 to 10 scale, where 0 corresponded to no discomfort and 10 corresponded to worst imaginable discomfort. A negative change from Baseline indicates the discomfort decreased.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="351"/>
                    <count group_id="O3" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.44" spread="2.219"/>
                    <measurement group_id="O2" value="-2.19" spread="2.120"/>
                    <measurement group_id="O3" value="-2.06" spread="2.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.88" spread="2.417"/>
                    <measurement group_id="O2" value="-2.90" spread="2.175"/>
                    <measurement group_id="O3" value="-2.56" spread="2.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.19" spread="2.454"/>
                    <measurement group_id="O2" value="-3.16" spread="2.362"/>
                    <measurement group_id="O3" value="-2.76" spread="2.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Abdominal Bloating Scores</title>
        <description>Symptoms of abdominal bloating were recorded on a 0 to 10 scale, where 0 corresponded to no bloating and 10 corresponded to worst imaginable bloating. A negative change from Baseline indicates the bloating decreased.</description>
        <time_frame>Baseline, Weeks 4, 12 and 26</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Abdominal Bloating Scores</title>
          <description>Symptoms of abdominal bloating were recorded on a 0 to 10 scale, where 0 corresponded to no bloating and 10 corresponded to worst imaginable bloating. A negative change from Baseline indicates the bloating decreased.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                    <count group_id="O2" value="305"/>
                    <count group_id="O3" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.89" spread="2.170"/>
                    <measurement group_id="O2" value="-1.80" spread="2.204"/>
                    <measurement group_id="O3" value="-1.73" spread="2.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="2.445"/>
                    <measurement group_id="O2" value="-2.41" spread="2.396"/>
                    <measurement group_id="O3" value="-2.08" spread="2.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="229"/>
                    <count group_id="O3" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="2.619"/>
                    <measurement group_id="O2" value="-2.68" spread="2.673"/>
                    <measurement group_id="O3" value="-2.17" spread="2.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Bowel Movements Per Day</title>
        <description>Participants recorded the number of bowel movements over 24 hours daily throughout the treatment.</description>
        <time_frame>Weeks 4, 12 and 26</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bowel Movements Per Day</title>
          <description>Participants recorded the number of bowel movements over 24 hours daily throughout the treatment.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>bowel movements per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="351"/>
                    <count group_id="O3" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="2.021"/>
                    <measurement group_id="O2" value="3.05" spread="1.962"/>
                    <measurement group_id="O3" value="3.38" spread="1.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="2.057"/>
                    <measurement group_id="O2" value="2.80" spread="1.685"/>
                    <measurement group_id="O3" value="3.15" spread="1.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="1.637"/>
                    <measurement group_id="O2" value="2.66" spread="1.625"/>
                    <measurement group_id="O3" value="2.96" spread="1.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Bowel Incontinence Episodes</title>
        <description>Participants recorded the number of incontinence episodes over 24 hours daily throughout the treatment.</description>
        <time_frame>Weeks 4, 12 and 26</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bowel Incontinence Episodes</title>
          <description>Participants recorded the number of incontinence episodes over 24 hours daily throughout the treatment.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="351"/>
                    <count group_id="O3" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="1.304"/>
                    <measurement group_id="O2" value="0.41" spread="1.230"/>
                    <measurement group_id="O3" value="0.50" spread="1.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="1.083"/>
                    <measurement group_id="O2" value="0.28" spread="0.875"/>
                    <measurement group_id="O3" value="0.46" spread="1.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.982"/>
                    <measurement group_id="O2" value="0.27" spread="0.844"/>
                    <measurement group_id="O3" value="0.50" spread="1.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Bowel Incontinence Free Days</title>
        <description>An incontinence free day was one where the participant reports zero incontinence episodes. The number of incontinence free days for a participant was assessed each week based on the number of reported days.</description>
        <time_frame>Weeks 4, 12 and 26</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bowel Incontinence Free Days</title>
          <description>An incontinence free day was one where the participant reports zero incontinence episodes. The number of incontinence free days for a participant was assessed each week based on the number of reported days.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="351"/>
                    <count group_id="O3" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.53" spread="2.282"/>
                    <measurement group_id="O2" value="5.46" spread="2.264"/>
                    <measurement group_id="O3" value="5.31" spread="2.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.38" spread="2.320"/>
                    <measurement group_id="O2" value="5.56" spread="2.164"/>
                    <measurement group_id="O3" value="5.28" spread="2.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.53" spread="2.129"/>
                    <measurement group_id="O2" value="5.59" spread="2.216"/>
                    <measurement group_id="O3" value="5.29" spread="2.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Urgency Episodes Per Day</title>
        <description>Participants recorded the number of urgency episodes over 24 hours daily throughout the treatment.</description>
        <time_frame>Weeks 4, 12 and 26</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Urgency Episodes Per Day</title>
          <description>Participants recorded the number of urgency episodes over 24 hours daily throughout the treatment.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="351"/>
                    <count group_id="O3" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="1.948"/>
                    <measurement group_id="O2" value="1.58" spread="1.732"/>
                    <measurement group_id="O3" value="2.00" spread="1.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="1.884"/>
                    <measurement group_id="O2" value="1.32" spread="1.675"/>
                    <measurement group_id="O3" value="1.73" spread="1.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="1.580"/>
                    <measurement group_id="O2" value="1.12" spread="1.576"/>
                    <measurement group_id="O3" value="1.54" spread="1.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IBS-QoL Total Scores</title>
        <description>The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100- point scale (0=worst; 100=better) for ease of interpretation. A positive change from Baseline indicates that quality of life improved.</description>
        <time_frame>Baseline, Weeks 4, 8, 12, 18, 26 and 30/EOT</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks treatment period followed by placebo orally, twice daily for next 4 weeks of blinded-placebo period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IBS-QoL Total Scores</title>
          <description>The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100- point scale (0=worst; 100=better) for ease of interpretation. A positive change from Baseline indicates that quality of life improved.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="342"/>
                    <count group_id="O3" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.51" spread="19.755"/>
                    <measurement group_id="O2" value="17.26" spread="18.980"/>
                    <measurement group_id="O3" value="14.07" spread="18.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="318"/>
                    <count group_id="O2" value="319"/>
                    <count group_id="O3" value="333"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.60" spread="20.762"/>
                    <measurement group_id="O2" value="21.10" spread="21.925"/>
                    <measurement group_id="O3" value="16.62" spread="20.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="300"/>
                    <count group_id="O3" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.69" spread="21.723"/>
                    <measurement group_id="O2" value="22.62" spread="24.017"/>
                    <measurement group_id="O3" value="19.50" spread="21.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="281"/>
                    <count group_id="O3" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.17" spread="22.761"/>
                    <measurement group_id="O2" value="23.52" spread="24.029"/>
                    <measurement group_id="O3" value="20.64" spread="23.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="258"/>
                    <count group_id="O2" value="271"/>
                    <count group_id="O3" value="277"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.91" spread="22.638"/>
                    <measurement group_id="O2" value="24.19" spread="24.599"/>
                    <measurement group_id="O3" value="21.50" spread="23.709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 30/EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="344"/>
                    <count group_id="O3" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.79" spread="22.329"/>
                    <measurement group_id="O2" value="20.92" spread="23.724"/>
                    <measurement group_id="O3" value="21.63" spread="23.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug up to 30 weeks</time_frame>
      <desc>Safety Set: all participants who received at least 1 dose of drug per actual treatment received. 1 participant in 100 mg arm received 75 mg, 2 participants in Placebo arm received eluxadoline 75 mg and 100 mg. AEs for each period were analyzed separately. In the Other AE section, a result of 0 in an arm means the ≥5% threshold was not met.</desc>
      <group_list>
        <group group_id="E1">
          <title>Eluxadoline 75 mg (Treatment Period)</title>
          <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks period.</description>
        </group>
        <group group_id="E2">
          <title>Eluxadoline 100 mg (Treatment Period)</title>
          <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks period.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Treatment Period)</title>
          <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks period.</description>
        </group>
        <group group_id="E4">
          <title>Eluxadoline 75 mg (Blinded-Placebo Period)</title>
          <description>Participants who received eluxadoline 75 mg in treatment period were administered with placebo orally, twice daily for next 4 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Eluxadoline 100 mg (Blinded-Placebo Period)</title>
          <description>Participants who received eluxadoline 100 mg in treatment period were administered with placebo orally, twice daily for next 4 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Placebo (Blinded-Placebo Period)</title>
          <description>Participants who received placebo matching tablets in treatment period were administered with placebo orally, twice daily for next 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Colitis ischemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Non-cardiac pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Enterocolitis infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pseudomeningocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ECG T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="380"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="381"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor will work with the Investigators to determine how any manuscript or publication in a scientific journal is written and edited, the number and order of authors, the publication to which it will be submitted, and other related issues. The sponsor has final approval authority over all such issues. Data are the property of the sponsor and cannot be published without prior authorization from the sponsor, but data and publication thereof will not be unduly withheld.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

